Email
28 Nov 2011

100-hour review is a ‘Trojan horse’, says Beta Buying Group

Business The Department of Health's review of control of entry regulations in England is "a Trojan horse, and one to be wary of", the head of a community...
Forgotten your password?
The page you are looking for is only available to logged in members of Chemist+Druggist.
Not a member yet?
Register now
If you are not a registered user, then please sign up here. Registering is free and takes just seconds. It gives you access to up-to-the minute news alerts and analysis, all our top bloggers.
If you experience any difficulties logging in or registering, or have any other questions, please contact Chemist+Druggist at haveyoursay@chemistanddruggist.co.uk
Comment on this article
You are not currently logged in. Login or register
Your Comments
A A, Community pharmacist
Posted on 28 November 2011.
I agree with Mr Govani's comment with regards to the distance-selling exemption. I think you may find Big-Pharma want to keep this exemption as it will enable them in the future, once EPS R2 is up and running, to offer to supply medicines direct-to-patient! DTP (direct-to-pharmacy) was only a stepping-stone to the next scenario IMHO. If you think I am wrong, why have GSK a registered pharmacy? Check out the GPhC website registrations if you don't believe me.
Sign in to vote.
Top

Please note You must be a registered user of Chemist+Druggist and logged in to add comments. Opinions expressed here are those of the writers and do not necessarily reflect those of Chemist+Druggist. Comments are considered in the public domain and may be used in future Chemist+Druggist coverage. We accept no responsibility, legal or otherwise, for the accuracy or the content of member comments.



 

Job of the week

Pharmacist & Technicians

Various locations

£45k + performance bonus

Follow C+D Jobs on